Discovery of S-217622, a SARS-covid CL Protease Inhibitor Clinical Candidate

0 views
Skip to first unread message

joseph...@msn.com

unread,
Jun 7, 2022, 11:01:56 PMJun 7
to
Discovery of S-217622, a Noncovalent Oral SARS-covid CL Protease Inhibitor Clinical Candidate
 
Protease Inhibitor and Clinical Candidate for SARS-covid

Tyndall et al

Abstract
"The coronavirus disease (COVID-19) pandemic has highlighted the ability to quickly react to the immense disease processes presented to the world. The orally available CL protease inhibitor S-217622 is currently progressing through clinical trials and its discovery from structure-based drug design, screening and optimization by Shionogi and Hokkaido University is presented

---------------

Discovery of S-217622, a Noncovalent Oral SARS-covid CL Protease Inhibitor Clinical Candidate


Reply all
Reply to author
Forward
0 new messages